AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

755.666

+7.7451.04%

Number of Gainers:17

Number of Losers:12

Number of Flat:16

PE:- -

High:756.356

Open:753.505

Low:749.555

Close:747.921

Volume:43.52M

Turnover:201.05M

Market Cap:114.75B

Float Cap:111.15B

Loading ...

How Investors May Respond To CSL (ASX:CSL) Securing NICE Approval and Appointing New CFO

Simply Wall St.

While Botanix Pharmaceuticals (ASX:BOT) shareholders have made 123% in 3 years, increasing losses might now be front of mind as stock sheds 12% this week

Simply Wall St.

Paradigm Biopharmaceuticals (ASX:PAR) Raises Capital—Will New Funds Accelerate Its Therapeutic Pipeline?

Simply Wall St.

Opthea Limited announces date for annual general meeting

Invion Raises About AU$800,000 via Convertible Notes Issue; Shares Rise 5%

MT Newswires Live

BRIEF-Medical Developments International Posts Group Revenue For Q1FY26 At A$10.9 MLN

BRIEF-Orthocell Ltd Reports Quarterly Revenue Of A$3.0 Million

With the portfolio up 35.36% (net) in 6 months, we have been searching for new stocks to drive the next wave of performance. Here are 2 we are adding

Orthocell Says US Rollout of Nerve Repair Product Ahead of Schedule; Shares Down 3%

MT Newswires Live

BUZZ-Australia's Medical Developments International gains on quarterly revenue growth

Medical Developments International - Group Revenue for Q1 FY26 at a$10.9 Mln

THOMSON REUTERS

Orthocell Ltd - Reports Quarterly Revenue of a$3.0 Mln

THOMSON REUTERS

CSL (ASX:CSL): Evaluating Valuation After Canadian Access Win for HEMGENIX Gene Therapy

Simply Wall St.

Immutep Announces Update for Tacti-004 (Keynote-F91) Phase Iii Trial in First Line Non-Small Cell Lung Cancer

THOMSON REUTERS

BUZZ-ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues

ASX Growth Companies With Insider Ownership October 2025

Simply Wall St.

Top Three High Growth Tech Stocks in Australia

Simply Wall St.

ASX Insights On Electro Optic Systems Holdings And 2 Other Stocks Priced Below Estimated Value

Simply Wall St.

Pegatron 5G Accelerates Make in India with Innovative 5G Small Cell and Smart Manufacturing at IMC 2025

Immuron Ltd - Plans Phase 2 Trial for Imm-529 in 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":755.666,"timestamp":1760072399855,"preClose":747.92145,"halted":0,"volume":43515793,"delay":0,"changeRate":0.010355,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":7.744568,"latestTime":"10-10 16:00:00 AEDT","open":753.5048,"high":756.3559,"low":749.5553,"amount":201050700,"amplitude":0.009093,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1760310000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1760050800000,1760072400000]],"turnoverRate":0.001558,"increases":13,"decrements":13,"flats":17,"marketCap":114748171758,"floatMarketCap":111152797876.5625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":756.3559,"amplitude":0.009093,"preClose":747.92145,"low":749.5553,"latestPrice":755.666,"volume":43515793,"delay":0,"open":753.5048,"prevYearClose":936.801,"prevWeekClose":749.725,"prevMonthClose":712.826,"prevQuarterClose":712.826,"fiveDayClose":749.725,"twentyDayClose":740.889,"sixtyDayClose":876.9,"secType":"PLATE","market":"AU","turnoverRate":0.001558,"marketCap":114748171758,"floatMarketCap":111152797876.5625,"timestamp":1760072399855,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":17,"down":12,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574045155","title":"How Investors May Respond To CSL (ASX:CSL) Securing NICE Approval and Appointing New CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2574045155","media":"Simply Wall St.","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574045155?lang=en_us&edition=fundamental","pubTime":"2025-10-11 18:27","pubTimestamp":1760178467,"startTime":"0","endTime":"0","summary":"CSL Limited recently appointed Ken Lim as its new Chief Financial Officer, succeeding Joy Linton, while also receiving final NICE guidance for NHS use of CSL Behring’s Andembry to prevent hereditary angioedema attacks in eligible UK patients.\nThis regulatory milestone for Andembry signals ongoing diversification and expansion of CSL’s specialty therapies, coinciding with leadership changes at a pivotal phase of the company’s operational transformation.\nWe’ll explore how CSL’s NICE approval...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-securing-nice-approv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-securing-nice-approv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BFMHRM44.USD","NICE","LU1169590202.USD","BK7067","SGXZ23171101.USD","BK7511","BK7501","BK4566","BK4023","LU1169589451.USD","BK4211","ISBC","BK7508","SG9999004303.SGD","BK4543","BK4086","LU0728928796.USD","CSL.AU","CSL"],"gpt_icon":0},{"id":"2574487931","title":"While Botanix Pharmaceuticals (ASX:BOT) shareholders have made 123% in 3 years, increasing losses might now be front of mind as stock sheds 12% this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2574487931","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574487931?lang=en_us&edition=fundamental","pubTime":"2025-10-11 06:37","pubTimestamp":1760135878,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Limited ( ASX:BOT ) shareholders might be concerned after seeing the share price drop 12% in...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/while-botanix-pharmaceuticals-asxbot-shareholders-have-made","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/while-botanix-pharmaceuticals-asxbot-shareholders-have-made","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7502","BOT.AU","BK7096"],"gpt_icon":0},{"id":"2574460483","title":"Paradigm Biopharmaceuticals (ASX:PAR) Raises Capital—Will New Funds Accelerate Its Therapeutic Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2574460483","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574460483?lang=en_us&edition=fundamental","pubTime":"2025-10-11 01:31","pubTimestamp":1760117508,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals recently announced the quotation of over 11 million new ordinary fully paid securities on the Australian Securities Exchange to enhance its financial flexibility.\nThis move aims to support the progress of therapies targeting inflammatory diseases, strengthening the company's position in musculoskeletal disorder treatment development.\nWe'll explore how raising capital for ongoing development projects shapes Paradigm Biopharmaceuticals’ investment narrative and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-asxpar-raises-capitalwill-new-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-asxpar-raises-capitalwill-new-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4157","BK4023","BK7067","BK7508","AAQC","PAR.AU","PAR"],"gpt_icon":0},{"id":"2574124091","title":"Opthea Limited announces date for annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2574124091","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574124091?lang=en_us&edition=fundamental","pubTime":"2025-10-10 18:03","pubTimestamp":1760090626,"startTime":"0","endTime":"0","summary":"Opthea Limited will hold its annual general meeting virtually on November 11, 2025. Shareholders will vote on the re-election of Dr. Jeremy Levin and Ms. Kathy Connell as directors, the adoption of the remuneration report, the issue of options to Mr. Lawrence Gozlan under the Non-Executive Directors Share and Option Plan, the issue of options to Ms. Kathy Connell under the same plan, and the issue of options to Dr. Jeremy Levin under the Long-Term Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL3BkyTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2574110753","title":"Invion Raises About AU$800,000 via Convertible Notes Issue; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574110753","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574110753?lang=en_us&edition=fundamental","pubTime":"2025-10-10 11:09","pubTimestamp":1760065767,"startTime":"0","endTime":"0","summary":"Invion  raised AU$782,254 through the issue of convertible notes, with an AU$11 face value, to funds and sophisticated investors, according to a Friday filing with the Australian bourse.The notes will be converted into shares at a price of AU$0.11 or the greater of AU$0.07 or 80% of the 15-day volume-weighted average price as of Feb. 28, 2026, the filing said.The notes will mature on either the date on which the agreement is signed or on Feb. 28, 2026, the filing added.Shares of the company rose 5% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","IVX.AU","BK7509","BK7508"],"gpt_icon":0},{"id":"2574621114","title":"BRIEF-Medical Developments International Posts Group Revenue For Q1FY26 At A$10.9 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2574621114","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574621114?lang=en_us&edition=fundamental","pubTime":"2025-10-10 09:36","pubTimestamp":1760060206,"startTime":"0","endTime":"0","summary":"BRIEF-Medical Developments International Posts Group Revenue For Q1FY26 At A$10.9 MLNOct 10 (Reuters) - Medical Developments International Ltd MVP.AX:GROUP REVENUE FOR Q1 FY26 AT A$10.9 MILLIONFurther company coverage: MVP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VQ1AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MVP.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2574960111","title":"BRIEF-Orthocell Ltd Reports Quarterly Revenue Of A$3.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2574960111","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574960111?lang=en_us&edition=fundamental","pubTime":"2025-10-10 09:17","pubTimestamp":1760059058,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Ltd Reports Quarterly Revenue Of A$3.0 MillionOct 10 (Reuters) - Orthocell Ltd OCC.AX:REPORTS QUARTERLY REVENUE OF A$3.0 MILLIONFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VQ1AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2574115097","title":"With the portfolio up 35.36% (net) in 6 months, we have been searching for new stocks to drive the next wave of performance.   Here are 2 we are adding","url":"https://stock-news.laohu8.com/highlight/detail?id=2574115097","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574115097?lang=en_us&edition=fundamental","pubTime":"2025-10-10 08:46","pubTimestamp":1760057166,"startTime":"0","endTime":"0","summary":"CSL Ltd  The top 3 plasma producers control ~85% of the US market.    CSL is the lowest cost operator with ~30% market share.   CSL reached a high of $290 per share in January but has declined markedly to the current level of around $210.  This was predominantly driven by potential issues around tariffs, margin contraction at Behring and confusion around the results presentation in August and spinoff of the vaccine business Seqirus.   Healthcare stocks have also lagged for the past 4 years, despite the strong long term outlook.  We consider these issues to be largely transient.  A clear base is now forming as sellers run out of conviction and sentiment begins to improve.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/with-the-portfolio-up-35-36-net-in-6-months-we-have-been-searching-for-new-stocks-to-drive-the-next-wave-of-performance-here-are-2-we-are-adding-2025-10-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/with-the-portfolio-up-35-36-net-in-6-months-we-have-been-searching-for-new-stocks-to-drive-the-next-wave-of-performance-here-are-2-we-are-adding-2025-10-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7149","CSL.AU","BK4589","LU1791807156.HKD","CSL","LU1169590202.USD","BK4211","LU1668664300.SGD","WAL","BK7067","SGXZ23171101.USD","LU0728928796.USD","BK7511","BK7156","HCW.AU","BK4588","BK4086","BK4585","BK7501","LU1169589451.USD","LU0106831901.USD","SG9999004303.SGD","BK7508"],"gpt_icon":0},{"id":"2574311332","title":"Orthocell Says US Rollout of Nerve Repair Product Ahead of Schedule; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574311332","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574311332?lang=en_us&edition=fundamental","pubTime":"2025-10-10 07:32","pubTimestamp":1760052752,"startTime":"0","endTime":"0","summary":"Orthocell  said the US rollout of its nerve repair product Remplir is well ahead of schedule, according to a Friday Australian bourse filing.The company expects Remplir's US revenue from early surgical cases to grow in the second half of the fiscal year, the filing said.Orthocell's shares were down almost 3% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2574311873","title":"BUZZ-Australia's Medical Developments International gains on quarterly revenue growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2574311873","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574311873?lang=en_us&edition=fundamental","pubTime":"2025-10-10 07:18","pubTimestamp":1760051936,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Medical Developments International gains on quarterly revenue growth** Shares of Medical Developments International MVP.AX rise as much as 12% to A$0.700, its biggest intraday gain si","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nL3N3VQ1KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MVP.AU"],"gpt_icon":0},{"id":"2574197436","title":"Medical Developments International - Group Revenue for Q1 FY26 at a$10.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2574197436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574197436?lang=en_us&edition=fundamental","pubTime":"2025-10-10 06:05","pubTimestamp":1760047500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VQ1AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MVP.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2574197156","title":"Orthocell Ltd - Reports Quarterly Revenue of a$3.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2574197156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574197156?lang=en_us&edition=fundamental","pubTime":"2025-10-10 06:01","pubTimestamp":1760047318,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nFWN3VQ1AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2574769114","title":"CSL (ASX:CSL): Evaluating Valuation After Canadian Access Win for HEMGENIX Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2574769114","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574769114?lang=en_us&edition=fundamental","pubTime":"2025-10-10 05:16","pubTimestamp":1760044608,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has secured a new agreement that will give more Canadians access to HEMGENIX, its innovative gene therapy for hemophilia B. The Letter of Intent with Canadian health authorities represents a meaningful step for patient access.\nSee our latest analysis for CSL.\nWhile this Canadian access win marks a bright spot for CSL, the bigger picture has been more challenging for shareholders. The past year’s -28.2% total shareholder return reflects both broad market pressures and investor...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-evaluating-valuation-after-canadian-access-win-fo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-evaluating-valuation-after-canadian-access-win-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7511","BK7501","BK4086","CSL","SG9999004303.SGD","SGXZ23171101.USD","LU1169589451.USD","BK7067","LU1169590202.USD","DCF","LU0728928796.USD","CSL.AU"],"gpt_icon":0},{"id":"2574115487","title":"Immutep Announces Update for Tacti-004 (Keynote-F91) Phase Iii Trial in First Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2574115487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574115487?lang=en_us&edition=fundamental","pubTime":"2025-10-09 20:00","pubTimestamp":1760011200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nTUAB9XPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2574189956","title":"BUZZ-ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2574189956","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574189956?lang=en_us&edition=fundamental","pubTime":"2025-10-09 12:04","pubTimestamp":1759982659,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues** Shares of inflammatory disease drug maker Mesoblast MSB.AX rise as much as 5.1% to A$3.07, their highest level since February 10** Bell Potter lifts FY26 revenue forecast 38% to A$108 mln  after drug Ryoncil's Sept quarter gross revenue of A$21.5 mln beat estimates** Brokerage expects Ryoncil revenues to rise each quarter, sees Sept quarter net revenue at A$19.1 mln** Expects positive 1H26 EBITDA and equity-based remuneration, operating cash surplus likely by 4Q26** Stock down 3.2% YTD, including the session's moves  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nL6N3VQ05W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","MSB.AU","BK7067"],"gpt_icon":0},{"id":"2574906930","title":"ASX Growth Companies With Insider Ownership October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574906930","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574906930?lang=en_us&edition=fundamental","pubTime":"2025-10-09 03:15","pubTimestamp":1759950920,"startTime":"0","endTime":"0","summary":"As the Australian market ended slightly in the red midweek, with gold prices reaching record highs and sectors experiencing mixed performances, investors are keenly observing trends that could influence future growth opportunities. In this context, companies with high insider ownership often attract attention as they can signal confidence from those who know the business best.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-resources-shares/news/asx-growth-companies-with-insider-ownership-october-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-resources-shares/news/asx-growth-companies-with-insider-ownership-october-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7043","XAO.AU","BK7036","BK7158","AV1.AU","BK7104","BK7093","NWF.AU","XKO.AU","AYA.AU","IR1.AU","BK7504","LTR.AU","3DP.AU","XJO.AU","TTT.AU","BK7116","BK7096","EIQ.AU","A4N.AU","BK7016","FND.AU","WZR.AU","ACR.AU","BK7017","BK7094","BK7095","IPX.AU","BK7508"],"gpt_icon":0},{"id":"2574906625","title":"Top Three High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2574906625","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574906625?lang=en_us&edition=fundamental","pubTime":"2025-10-09 03:10","pubTimestamp":1759950635,"startTime":"0","endTime":"0","summary":"As the Australian market remains relatively stable with the ASX ending slightly in the red midweek, investors are keeping a keen eye on sectors showing resilience and potential for growth, particularly within the tech space. In this environment, identifying high growth tech stocks requires attention to companies that not only navigate current economic conditions effectively but also demonstrate innovation and adaptability amidst broader market sentiment.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/top-three-high-growth-tech-stocks-in-australia","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/top-three-high-growth-tech-stocks-in-australia","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7503","BK7508","XAO.AU","XJO.AU","CUV.AU","BK7094","AYA.AU","XKO.AU","BK7067","IFM.AU","BK7016"],"gpt_icon":0},{"id":"2574644906","title":"ASX Insights On Electro Optic Systems Holdings And 2 Other Stocks Priced Below Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2574644906","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574644906?lang=en_us&edition=fundamental","pubTime":"2025-10-09 03:08","pubTimestamp":1759950513,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of mixed performance, with the ASX ending flat midweek and US futures showing unreliable signals, investors are keenly observing sectors that might offer hidden value. In such an environment, identifying undervalued stocks like Electro Optic Systems Holdings can be crucial for those looking to capitalize on discrepancies between current prices and estimated intrinsic values.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-insights-on-electro-optic-systems-holdings-and-2-other-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-insights-on-electro-optic-systems-holdings-and-2-other-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7117","BK7160","BK7115","SLC.AU","BK7016","BK7067","BK7047","CYP.AU","NWH.AU","BK7055","EOS.AU","ART.AU","XJO.AU","XKO.AU","BK7508","BK7501","RMC.AU","XAO.AU","BK7505","RKN.AU","BK7084","BK7015","BK7044","BK7007","SPZ.AU","BK7123","CSX.AU","ELD.AU","JHX.AU","BK7002"],"gpt_icon":0},{"id":"2573923391","title":"Pegatron 5G Accelerates Make in India with Innovative 5G Small Cell and Smart Manufacturing at IMC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923391","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923391?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:11","pubTimestamp":1759925460,"startTime":"0","endTime":"0","summary":"NEW DELHI, Oct. 8, 2025 /PRNewswire/ -- Pegatron 5G, a new business unit of Pegatron, a globally leading manufacturing company announces its participation at the India Mobile Congress  2025, the nation's largest digital technology event with the theme \"Innovation: The Engine of India's Progress\", Pegatron 5G will play the role of supplying advanced 5G technology in accelerating transformation across industries thus paving the way for Viksit Bharat 2047.Pegatron 5G showcase its 5G Radio portfolio at IMC 2025. RedCap:the integration of PG5200, Muscat, MD200, PR1450, and PS1400 - designed to provide a cost-effective and power-efficient way to connect industrial and IoT devices to 5G networks. RedCap devices are simpler, with reduced RF chain complexity and lower bandwidth requirements. For network operators or enterprise/private networks, simpler devices and reduced throughput demands can reduce infrastructure and ongoing operational costs.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2791423/20251008_073123728_iOS.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2791423/20251008_073123728_iOS.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pegatron-5g-accelerates-make-in-india-with-innovative-5g-small-cell-and-smart-manufacturing-at-imc-2025-302578310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNDmain","BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2573448719","title":"Immuron Ltd - Plans Phase 2 Trial for Imm-529 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573448719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573448719?lang=en_us&edition=fundamental","pubTime":"2025-10-08 18:00","pubTimestamp":1759917600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA3Y2GPG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":109,"code":"91000000","status":"200"}]}}